Medpace Quarterly Income Statement
NASDAQ: MEDPHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Medpace revenue and earnings
In the quarter ended Jun 30, 2026, Medpace generated $707.3 million in revenue, up 17.2% from the same quarter a year earlier. Net income was $121.4 million (+34.5% year over year), for a net margin of 17.2% versus a median of 17.5% in the prior 5 quarters. Operating margin was 20.8%.
Diluted earnings per share came in at $4.25, up from $3.10.
Summary generated from market data by MetaCap's automated system. Methodology
Medpace income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 707.33M | 706.60M | 708.45M | 659.90M | 603.31M | 558.57M | 536.59M | 533.32M | 528.10M | 511.04M | 498.40M | 492.50M |
| Revenue growth (YoY) | +17.24% | +26.50% | +32.03% | +23.74% | +14.24% | +9.30% | +7.66% | +8.29% | +14.59% | +17.73% | +26.47% | +28.34% |
| Selling, General & Admin | 48.10M | 47.92M | 44.92M | 48.08M | 46.66M | 57.90M | 45.43M | 49.22M | 41.45M | 44.08M | 42.51M | 41.41M |
| Operating Income | 146.82M | 141.50M | 153.27M | 141.81M | 126.33M | 113.52M | 125.38M | 112.27M | 105.15M | 104.07M | 87.32M | 84.91M |
| Other Income (Expense) | 4.84M | 6.09M | 3.56M | 1.03M | -1.80M | 4.65M | 8.50M | 6.50M | 5.33M | 8.71M | 3.39M | -1.71M |
| Pretax Income | 151.66M | 147.59M | 156.83M | 142.84M | 124.54M | 118.17M | 133.88M | 118.78M | 110.48M | 112.78M | 90.71M | 83.20M |
| Income Tax | 30.30M | 23.72M | 21.70M | 31.70M | 34.28M | 3.58M | 16.86M | 22.35M | 22.13M | 10.19M | 12.41M | 12.65M |
| Net Income | 121.36M | 123.87M | 135.13M | 111.14M | 90.26M | 114.59M | 117.02M | 96.43M | 88.35M | 102.59M | 78.30M | 70.55M |
| Net Income growth (YoY) | +34.46% | +8.09% | +15.48% | +15.25% | +2.16% | +11.70% | +49.45% | +36.68% | +44.68% | +40.74% | +14.02% | +6.85% |
| EPS (Basic) | 4.31 | 4.35 | 4.76 | 3.95 | 3.16 | 3.77 | 3.78 | 3.11 | 2.85 | 3.32 | 2.55 | 2.30 |
| EPS (Diluted) | 4.25 | 4.28 | 4.65 | 3.86 | 3.10 | 3.67 | 3.67 | 3.01 | 2.75 | 3.20 | 2.46 | 2.22 |
| Shares Outstanding (Basic) | 28.17M | 28.45M | — | 28.14M | 28.60M | 30.39M | — | 31.05M | 30.99M | 30.84M | — | 30.63M |
| Shares Outstanding (Diluted) | 28.55M | 28.96M | — | 28.82M | 29.14M | 31.20M | — | 32.09M | 32.09M | 32.00M | — | 31.76M |
| EBITDA | 153.38M | 148.25M | 160.16M | 148.62M | 133.11M | 120.22M | 132.52M | 119.43M | 112.02M | 110.70M | 93.74M | 91.24M |
| Operating Margin | 20.76% | 20.03% | 21.63% | 21.49% | 20.94% | 20.32% | 23.37% | 21.05% | 19.91% | 20.36% | 17.52% | 17.24% |
| Net Margin | 17.16% | 17.53% | 19.07% | 16.84% | 14.96% | 20.52% | 21.81% | 18.08% | 16.73% | 20.07% | 15.71% | 14.32% |
This table shows 12 quarterly periods of Medpace's income statement, from Q2 2026 back to Q3 2023, across 14 line items including revenue, selling, general & admin, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow MEDP's reporting calendar. What is a income statement?